← FDA DRUG APPROVALS

FDA ANDA · ANDA215957

PIXXOSCAN

Sponsor: GE HLTHCARE

APPLICATION
ANDA215957
TYPE
ANDA
ORIGINAL APPROVAL
2026-06-29
LATEST ACTION
2026-06-29
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

PIXXOSCANPrescription
GADOBUTROL 4.5354GM/7.5ML (604.72MG/ML) · SOLUTION · INTRAVENOUS
PIXXOSCANPrescription
GADOBUTROL 6.0472GM/10ML (604.72MG/ML) · SOLUTION · INTRAVENOUS
PIXXOSCANPrescription
GADOBUTROL 1.20944GM/2ML (604.72MG/ML) · SOLUTION · INTRAVENOUS
PIXXOSCANPrescription
GADOBUTROL 9.0708GM/15ML (604.72MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2026-06-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →